RecruitingNot ApplicableNCT03729115

A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

Chicago Alternative Prevention Study for Diverse Populations of High Risk Women


Sponsor

University of Chicago

Enrollment

400 participants

Start Date

May 30, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.


Eligibility

Sex: FEMALEMin Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying an enhanced screening program using multiple imaging methods to detect breast cancer early in women who are at very high risk for developing the disease due to genetic mutations or other risk factors. **You may be eligible if...** - You carry a known high-risk gene mutation (such as BRCA1, BRCA2, TP53, PALB2, PTEN, CDH1, or STK11) - Your lifetime risk of breast cancer is 30% or higher based on genetic and non-genetic risk scores - Your 5-year risk of breast cancer is 6% or higher (for women aged 40–64 or 65+) - Women 65+ may also qualify with dense breast tissue and a lifetime risk of 20% or more - You are female and have not had breast cancer **You may NOT be eligible if...** - You have a personal history of breast cancer - You do not meet the high-risk genetic or statistical criteria above - You are unable to undergo MRI or other imaging Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREMagnetic Resonance Imaging (MRI)

Patients will have MRI scans every 6 months.


Locations(1)

University Of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03729115


Related Trials